الفهرس 
Ventilator Associated Pneumonia
In the mechanically ventilated patientOnly 14 pages are availabe for public view
 |  | from | 32 |  |  |
| | | from | 32 | | |
Abstract
Ventilator-associated pneumonia (VAP) remains one
of the most common ICU acquired infections and is
associated with greater ICU length of stay, mortality, and
healthcare costs.
Inadequate initial antimicrobial treatment of VAP is
associated with adverse outcomes; however, early adequate
therapy is increasingly more difficult to achieve.
The misuse of antibiotics in ICU increase significantly
the emergence of resistant bacterial strains which in role
negatively affects the efficacy of treatment of VAP, So the
Prevention of VAP is the main corner stone of decreasing its
prevalence in critically ill patients.
Intravenously administered antibiotics are primarily
detected in respiratory segments of lungs, but not in sputum
in contrast aerosol antibiotics administration offers the
theoretical advantages of achieving high drug concentrations
at the infection site and low systemic absorption.
Large studies are needed for evaluating the efficacy of
aerosolized antibiotics in treatment of VAP and the
possibility of their use as prophylactic and empirical standalone therapies, thus minimizing systemic antibiotics side
effects and toxicity.